Cargando…

Neutrophile-to-lymphocyte, lymphocyte-to-monocyte, and platelet-to-lymphocyte ratios as prognostic and response biomarkers for resectable locally advanced gastric cancer

BACKGROUND: Perioperative fluorouracil plus leucovorin, oxaliplatin, and docetaxel (FLOT) improves prognosis in locally advanced gastric cancer (LAGC). Neutrophil-to-lymphocyte (NLR), lymphocyte-to-monocyte (LMR), and platelet-to-lymphocyte (PLR) ratios are prognostic biomarkers but not predictive f...

Descripción completa

Detalles Bibliográficos
Autores principales: Tomás, Tiago Cruz, Eiriz, Inês, Vitorino, Marina, Vicente, Rodrigo, Gramaça, João, Oliveira, Alicia Guadalupe, Luz, Paulo, Baleiras, Mafalda, Spencer, Ana Sofia, Costa, Luísa Leal, Liu, Patrícia, Mendonça, Joana, Dinis, Magno, Padrão, Teresa, Correia, Marisol, Atalaia, Gonçalo, Silva, Michelle, Fiúza, Teresa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305575/
https://www.ncbi.nlm.nih.gov/pubmed/36051098
http://dx.doi.org/10.4251/wjgo.v14.i7.1307
_version_ 1784752359734247424
author Tomás, Tiago Cruz
Eiriz, Inês
Vitorino, Marina
Vicente, Rodrigo
Gramaça, João
Oliveira, Alicia Guadalupe
Luz, Paulo
Baleiras, Mafalda
Spencer, Ana Sofia
Costa, Luísa Leal
Liu, Patrícia
Mendonça, Joana
Dinis, Magno
Padrão, Teresa
Correia, Marisol
Atalaia, Gonçalo
Silva, Michelle
Fiúza, Teresa
author_facet Tomás, Tiago Cruz
Eiriz, Inês
Vitorino, Marina
Vicente, Rodrigo
Gramaça, João
Oliveira, Alicia Guadalupe
Luz, Paulo
Baleiras, Mafalda
Spencer, Ana Sofia
Costa, Luísa Leal
Liu, Patrícia
Mendonça, Joana
Dinis, Magno
Padrão, Teresa
Correia, Marisol
Atalaia, Gonçalo
Silva, Michelle
Fiúza, Teresa
author_sort Tomás, Tiago Cruz
collection PubMed
description BACKGROUND: Perioperative fluorouracil plus leucovorin, oxaliplatin, and docetaxel (FLOT) improves prognosis in locally advanced gastric cancer (LAGC). Neutrophil-to-lymphocyte (NLR), lymphocyte-to-monocyte (LMR), and platelet-to-lymphocyte (PLR) ratios are prognostic biomarkers but not predictive factors. AIM: To assess blood ratios’ (NLR, LMR and PLR) potential predictive response to FLOT and survival outcomes in resectable LAGC patients. METHODS: This was a multicentric retrospective study investigating the clinical potential of NLR, LMR, and PLR in resectable LAGC patients, treated with at least one preoperative FLOT cycle, from 12 Portuguese hospitals. Means were compared through non-parametric Mann-Whitney tests. Receiver operating characteristic curve analysis defined the cut-off values as: High PLR > 141 for progression and > 144 for mortality; high LMR > 3.56 for T stage regression (TSR). Poisson and Cox regression models the calculated relative risks/hazard ratios, using NLR, pathologic complete response, TSR, and tumor regression grade (TRG) as independent variables, and overall survival (OS) as the dependent variable. RESULTS: This study included 295 patients (mean age, 63.7 years; 59.7% males). NLR was correlated with survival time (r = 0.143, P = 0.014). PLR was associated with systemic progression during FLOT (P = 0.022) and mortality (P = 0.013), with high PLR patients having a 2.2-times higher risk of progression [95% confidence interval (CI): 0.89-5.26] and 1.5-times higher risk of mortality (95%CI: 0.92-2.55). LMR was associated with TSR, and high LMR patients had a 1.4-times higher risk of achieving TSR (95%CI: 1.01-1.99). OS benefit was found with TSR (P = 0.015) and partial/complete TRG (P < 0.001). Patients without TSR and with no evidence of pathological response had 2.1-times (95%CI: 1.14-3.96) and 2.8-times (95%CI: 1.6-5) higher risk of death. CONCLUSION: Higher NLR is correlated with longer survival time. High LMR patients have a higher risk of decreasing T stage, whereas high PLR patients have higher odds of progressing under FLOT and dying. Patients with TSR and a pathological response have better OS and lower risk of dying.
format Online
Article
Text
id pubmed-9305575
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-93055752022-08-31 Neutrophile-to-lymphocyte, lymphocyte-to-monocyte, and platelet-to-lymphocyte ratios as prognostic and response biomarkers for resectable locally advanced gastric cancer Tomás, Tiago Cruz Eiriz, Inês Vitorino, Marina Vicente, Rodrigo Gramaça, João Oliveira, Alicia Guadalupe Luz, Paulo Baleiras, Mafalda Spencer, Ana Sofia Costa, Luísa Leal Liu, Patrícia Mendonça, Joana Dinis, Magno Padrão, Teresa Correia, Marisol Atalaia, Gonçalo Silva, Michelle Fiúza, Teresa World J Gastrointest Oncol Retrospective Study BACKGROUND: Perioperative fluorouracil plus leucovorin, oxaliplatin, and docetaxel (FLOT) improves prognosis in locally advanced gastric cancer (LAGC). Neutrophil-to-lymphocyte (NLR), lymphocyte-to-monocyte (LMR), and platelet-to-lymphocyte (PLR) ratios are prognostic biomarkers but not predictive factors. AIM: To assess blood ratios’ (NLR, LMR and PLR) potential predictive response to FLOT and survival outcomes in resectable LAGC patients. METHODS: This was a multicentric retrospective study investigating the clinical potential of NLR, LMR, and PLR in resectable LAGC patients, treated with at least one preoperative FLOT cycle, from 12 Portuguese hospitals. Means were compared through non-parametric Mann-Whitney tests. Receiver operating characteristic curve analysis defined the cut-off values as: High PLR > 141 for progression and > 144 for mortality; high LMR > 3.56 for T stage regression (TSR). Poisson and Cox regression models the calculated relative risks/hazard ratios, using NLR, pathologic complete response, TSR, and tumor regression grade (TRG) as independent variables, and overall survival (OS) as the dependent variable. RESULTS: This study included 295 patients (mean age, 63.7 years; 59.7% males). NLR was correlated with survival time (r = 0.143, P = 0.014). PLR was associated with systemic progression during FLOT (P = 0.022) and mortality (P = 0.013), with high PLR patients having a 2.2-times higher risk of progression [95% confidence interval (CI): 0.89-5.26] and 1.5-times higher risk of mortality (95%CI: 0.92-2.55). LMR was associated with TSR, and high LMR patients had a 1.4-times higher risk of achieving TSR (95%CI: 1.01-1.99). OS benefit was found with TSR (P = 0.015) and partial/complete TRG (P < 0.001). Patients without TSR and with no evidence of pathological response had 2.1-times (95%CI: 1.14-3.96) and 2.8-times (95%CI: 1.6-5) higher risk of death. CONCLUSION: Higher NLR is correlated with longer survival time. High LMR patients have a higher risk of decreasing T stage, whereas high PLR patients have higher odds of progressing under FLOT and dying. Patients with TSR and a pathological response have better OS and lower risk of dying. Baishideng Publishing Group Inc 2022-07-15 2022-07-15 /pmc/articles/PMC9305575/ /pubmed/36051098 http://dx.doi.org/10.4251/wjgo.v14.i7.1307 Text en ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
spellingShingle Retrospective Study
Tomás, Tiago Cruz
Eiriz, Inês
Vitorino, Marina
Vicente, Rodrigo
Gramaça, João
Oliveira, Alicia Guadalupe
Luz, Paulo
Baleiras, Mafalda
Spencer, Ana Sofia
Costa, Luísa Leal
Liu, Patrícia
Mendonça, Joana
Dinis, Magno
Padrão, Teresa
Correia, Marisol
Atalaia, Gonçalo
Silva, Michelle
Fiúza, Teresa
Neutrophile-to-lymphocyte, lymphocyte-to-monocyte, and platelet-to-lymphocyte ratios as prognostic and response biomarkers for resectable locally advanced gastric cancer
title Neutrophile-to-lymphocyte, lymphocyte-to-monocyte, and platelet-to-lymphocyte ratios as prognostic and response biomarkers for resectable locally advanced gastric cancer
title_full Neutrophile-to-lymphocyte, lymphocyte-to-monocyte, and platelet-to-lymphocyte ratios as prognostic and response biomarkers for resectable locally advanced gastric cancer
title_fullStr Neutrophile-to-lymphocyte, lymphocyte-to-monocyte, and platelet-to-lymphocyte ratios as prognostic and response biomarkers for resectable locally advanced gastric cancer
title_full_unstemmed Neutrophile-to-lymphocyte, lymphocyte-to-monocyte, and platelet-to-lymphocyte ratios as prognostic and response biomarkers for resectable locally advanced gastric cancer
title_short Neutrophile-to-lymphocyte, lymphocyte-to-monocyte, and platelet-to-lymphocyte ratios as prognostic and response biomarkers for resectable locally advanced gastric cancer
title_sort neutrophile-to-lymphocyte, lymphocyte-to-monocyte, and platelet-to-lymphocyte ratios as prognostic and response biomarkers for resectable locally advanced gastric cancer
topic Retrospective Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305575/
https://www.ncbi.nlm.nih.gov/pubmed/36051098
http://dx.doi.org/10.4251/wjgo.v14.i7.1307
work_keys_str_mv AT tomastiagocruz neutrophiletolymphocytelymphocytetomonocyteandplatelettolymphocyteratiosasprognosticandresponsebiomarkersforresectablelocallyadvancedgastriccancer
AT eirizines neutrophiletolymphocytelymphocytetomonocyteandplatelettolymphocyteratiosasprognosticandresponsebiomarkersforresectablelocallyadvancedgastriccancer
AT vitorinomarina neutrophiletolymphocytelymphocytetomonocyteandplatelettolymphocyteratiosasprognosticandresponsebiomarkersforresectablelocallyadvancedgastriccancer
AT vicenterodrigo neutrophiletolymphocytelymphocytetomonocyteandplatelettolymphocyteratiosasprognosticandresponsebiomarkersforresectablelocallyadvancedgastriccancer
AT gramacajoao neutrophiletolymphocytelymphocytetomonocyteandplatelettolymphocyteratiosasprognosticandresponsebiomarkersforresectablelocallyadvancedgastriccancer
AT oliveiraaliciaguadalupe neutrophiletolymphocytelymphocytetomonocyteandplatelettolymphocyteratiosasprognosticandresponsebiomarkersforresectablelocallyadvancedgastriccancer
AT luzpaulo neutrophiletolymphocytelymphocytetomonocyteandplatelettolymphocyteratiosasprognosticandresponsebiomarkersforresectablelocallyadvancedgastriccancer
AT baleirasmafalda neutrophiletolymphocytelymphocytetomonocyteandplatelettolymphocyteratiosasprognosticandresponsebiomarkersforresectablelocallyadvancedgastriccancer
AT spenceranasofia neutrophiletolymphocytelymphocytetomonocyteandplatelettolymphocyteratiosasprognosticandresponsebiomarkersforresectablelocallyadvancedgastriccancer
AT costaluisaleal neutrophiletolymphocytelymphocytetomonocyteandplatelettolymphocyteratiosasprognosticandresponsebiomarkersforresectablelocallyadvancedgastriccancer
AT liupatricia neutrophiletolymphocytelymphocytetomonocyteandplatelettolymphocyteratiosasprognosticandresponsebiomarkersforresectablelocallyadvancedgastriccancer
AT mendoncajoana neutrophiletolymphocytelymphocytetomonocyteandplatelettolymphocyteratiosasprognosticandresponsebiomarkersforresectablelocallyadvancedgastriccancer
AT dinismagno neutrophiletolymphocytelymphocytetomonocyteandplatelettolymphocyteratiosasprognosticandresponsebiomarkersforresectablelocallyadvancedgastriccancer
AT padraoteresa neutrophiletolymphocytelymphocytetomonocyteandplatelettolymphocyteratiosasprognosticandresponsebiomarkersforresectablelocallyadvancedgastriccancer
AT correiamarisol neutrophiletolymphocytelymphocytetomonocyteandplatelettolymphocyteratiosasprognosticandresponsebiomarkersforresectablelocallyadvancedgastriccancer
AT atalaiagoncalo neutrophiletolymphocytelymphocytetomonocyteandplatelettolymphocyteratiosasprognosticandresponsebiomarkersforresectablelocallyadvancedgastriccancer
AT silvamichelle neutrophiletolymphocytelymphocytetomonocyteandplatelettolymphocyteratiosasprognosticandresponsebiomarkersforresectablelocallyadvancedgastriccancer
AT fiuzateresa neutrophiletolymphocytelymphocytetomonocyteandplatelettolymphocyteratiosasprognosticandresponsebiomarkersforresectablelocallyadvancedgastriccancer